With nivolumab/ipilimumab, there was a trend towards a better prognosis for patients with tumor specimen PD-L1 expression ≥1% in CheckMate 214 42, but this trend was not evident for nivolumab in CheckMate 025 43. This evidence concerns the gene CD274 and neoplasm.